By Jonathan Kron
Healthcare AI investment is booming, with $10.7 billion invested this year alone, 24% more than last year. However, startup adoption lags due to healthcare’s regulatory cycles, contrasting the rapid growth expectations of investors. According to Bessemer Venture Partners, only 30% of health AI projects reach production, highlighting a gap between venture speed and system absorption. Founders pressured by short-term gains prioritize momentum over clinical integration, often building features to attract funding rather than real adoption, resulting in high costs with little systemic change. The crux lies in mismatched timelines; healthcare values trust, validation, and interoperability, which take years to develop and deliver compounded value unlike consumer tech’s speed advantage. Success in healthcare AI depends on truly integrating with clinicians, understanding compliance, data standards, and workflows, and focusing on clinical problems rather than hype. The “AI wellness” sector enjoys quick growth but lacks validation, whereas “AI clinical” solutions progress slower but provide lasting impact and defensible value. For lasting success, founders must align with knowledgeable investors who value patient capital, build solutions for adoption over hype, and prioritize regulatory compliance and clinical outcomes. Patient investors backing integration-oriented companies with long-term vision will ultimately shape the foundational platforms for global health systems. Jonathan Kron, CEO of BloodGPT, advocates for this patient approach to healthcare AI investing, emphasizing that transformative impact and sustained returns require time and trust.
Back
